Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS

Publisher: La Merie Publishing
Pages: 75
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0157
Release Date: November of 2016

500.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS

This Competitive Intelligence report about Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS provides a competitor evaluation as of November 2016 in the field of antibodies, proteins and vaccines stimulating immune checkpoints from the TNF receptor and the B7-CD28 superfamilies, including

  • CD40 (TNFSFR5)
  • GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
  • OX40 (CD134; TNFSFR4)
  • 4-1BB (CD137; TNFSFR9)
  • CD27 (TNFSFR7)
  • ICOS (Inducible Co-Stimulator)

Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

More than 20 immune checkpoint agonistic antibodies are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further six molecules are undergoing IND-enabling studies.

The report includes a compilation of currently active projects in research and development of immune checkpoint activators. In addition, the report lists company-specific R&D pipelines of PD-1 and PD-L1 Immune Checkpoint Inhibitors. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS

Table of Contents

1)        Immune Checkpoint Activators

  • CD40 Agonists
  • Glucocorticoid-Induced Tumor Necrosis Factor Receptor (GITR) Stimulators
  • OX40 Agonists
  • 4-1BB (CD137) Agonists
  • CD27 Agonists
  • Inducible Co-Stimulator Molecule (ICOS) Agonists
  • Other Activators

2)        Corporate Immune Checkpoint Activators R&D Pipeline

 



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top